enGene Holdings Inc. (ENGN)

Ron Cooper was appointed as the Chief Executive Officer on July 24, 2025. On September 11, 2025, the company achieved its target enrollment milestone for the LEGEND trial's pivotal cohort and received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for detalimogene. On November 11, 2025, enGene reported updated preliminary data from LEGEND's pivotal cohort, demonstrating an improved 6-month complete response rate of 62% in patients enrolled under an amended protocol. enGene announced and subsequently priced a $130 million public offering of common shares and pre-funded warrants on November 12-13, 2025. The company presented at the Jefferies Global Healthcare Conference in London on November 18, 2025, and at the Piper Sandler 37th Annual Healthcare Conference on November 25, 2025. Detalimogene was selected for the FDA Manufacturing Pilot Program on December 2, 2025. On December 22, 2025, enGene reported its full-year 2025 financial results and provided a business update, confirming the completed enrollment of 125 patients in LEGEND's pivotal cohort. The share price was $8.85 on January 2, 2026, reflecting an 18.16% increase from January 6, 2025. On January 7, 2026, the stock price was $8.50, experiencing a 13.79% decrease from the previous day. The stock price was $8.38 on January 13, 2026.

As a clinical-stage biotechnology company, enGene Holdings, Inc. does not currently experience direct demand seasonality for its products and services in the commercial market. The demand at this stage is primarily related to investor interest, the progress of its clinical development programs, and the enrollment in its clinical trials. Notably, the company reported that enrollment in its LEGEND pivotal cohort exceeded its original target by 25%, driven by investigator demand.

enGene Holdings, Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for local administration into mucosal tissues and other organs, primarily addressing urological cancers. Their lead product candidate is detalimogene voraplasmid, a monotherapy for non-muscle invasive bladder cancer (NMIBC), developed using their proprietary Dually Derivatized Oligochitosan (DDX) platform. The company is currently evaluating detalimogene in the multi-cohort LEGEND Phase II study.

enGene Holdings, Inc. is headquartered in Saint-Laurent, Quebec, Canada, and has expanded its clinical footprint for the LEGEND study by adding trial sites in Europe and Asia.

enGene Holdings, Inc.'s brand reputation has been positively influenced by the achievement of target enrollment for its pivotal LEGEND trial cohort, the granting of Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for detalimogene, and the selection of detalimogene for the FDA Manufacturing Pilot Program. Positive preliminary clinical trial data, such as the 62% complete response rate at 6 months for detalimogene, further enhances its standing. However, the company's shareholder returns have underperformed the US Biotechs industry and the broader US market over the past year, which could be viewed negatively by investors.

enGene Holdings Inc. has 46 institutional owners and shareholders, holding a total of 40,998,963 shares. Private equity firms hold the largest stake, possessing 43% of the shares, while institutions own 32%. Hedge funds account for 7.5% of ownership, and the general public holds 17%. Individual insiders own less than 1% of the company. Major institutional and individual owners include Forbion Capital Partners B.V., Perceptive Advisors LLC, VR Management, LLC, Kynam Capital Management, LP, Deep Track Capital, LP, Lumira Capital Investment Management Inc., CHI Advisors LLC, Blue Owl Capital Holdings LP, Cormorant Asset Management, LP, Point72 Asset Management, L.P., Frazier Life Sciences Management, L.P., Venrock Healthcare Capital Partners III, L.P., and Adage Capital Management, L.P.